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ARTICLE
SUMO-mediated regulation of NLRP3 modulates
inﬂammasome activity
Rachael Barry 1,2, Sidonie Wicky John1, Gianmaria Liccardi1, Tencho Tenev1, Isabel Jaco1, Chih-Hong Chen3,
Justin Choi3, Paulina Kasperkiewicz4, Teresa Fernandes-Alnemri5, Emad Alnemri5, Marcin Drag4, Yuan Chen3 &
Pascal Meier1
The NLRP3 inﬂammasome responds to infection and tissue damage, and rapidly escalates the
intensity of inﬂammation by activating interleukin (IL)-1β, IL-18 and cell death by pyroptosis.
How the NLRP3 inﬂammasome is negatively regulated is poorly understood. Here we show
that NLRP3 inﬂammasome activation is suppressed by sumoylation. NLRP3 is sumoylated by
the SUMO E3-ligase MAPL, and stimulation-dependent NLRP3 desumoylation by the
SUMO-speciﬁc proteases SENP6 and SENP7 promotes NLRP3 activation. Defective
NLRP3 sumoylation, either by NLRP3 mutation of SUMO acceptor lysines or depletion of
MAPL, results in enhanced caspase-1 activation and IL-1β release. Conversely, depletion of
SENP7 suppresses NLRP3-dependent ASC oligomerisation, caspase-1 activation and IL-1β
release. These data indicate that sumoylation of NLRP3 restrains inﬂammasome activation,
and identify SUMO proteases as potential drug targets for the treatment of inﬂammatory
diseases.
DOI: 10.1038/s41467-018-05321-2 OPEN
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Inﬂammasomes are key signalling complexes of the innateimmune system that drive activation of caspase-1 in responseto microbial and non-microbial danger signals1, including
pathogen-derived proteins, lipids, nucleic acids, polysaccharides,
crystalline materials, extracellular ATP, speciﬁc host proteins, and
alterations in ion levels and osmolarity. Activation of caspase-1
results in the cleavage and maturation of the highly inﬂammatory
cytokines interleukin (IL)-1β and IL-182. In addition, caspase-1
also cleaves gasdermin-D, which triggers programmed inﬂam-
matory cell death (pyroptosis) that enables the release of IL-1β,
IL-18 and other DAMPs3,4. Tight regulation of inﬂammasome
activation is crucial as aberrant or excessive activation of caspase-
1 is associated with various diseases including gout disease, type-
II diabetes, Alzheimer’s disease and atherosclerosis5–10. Accord-
ingly, genetic mutations that result in uncontrolled activation of
the NLRP3 inﬂammasome are linked to cryopyrinopathies or
cryopyrin-associated periodic fever syndromes (CAPS)5.
Upon exposure to exogenous or endogenous stimuli, NLRP3
assembles a canonical multimeric inﬂammasome complex com-
prising the adaptor Apoptosis-associated speck-like protein con-
taining a CARD (ASC) and the effector pro-caspase-1 to mediate
the activation of caspase-111. At present, there is no evidence of
direct ligand binding by NLRP3, which led to the hypothesis that
NLRP3 senses changes in the cellular milieu. Numerous activa-
tion models for the NLRP3 inﬂammasome have been proposed
including lysosomal rupture, mitochondrial damage, ROS pro-
duction, potassium efﬂux and plasma membrane rupture
(reviewed in12,13). However, despite considerable efforts, the
precise mechanism by which NLRP3 senses these cellular changes
remains unclear.
NLRP3 is expressed by myeloid cells and is up-regulated in
response to the stimulation of macrophages with pathogen-
associated molecule patterns (PAMPs)14. A two-signal model has
emerged for NLRP3/ASC/caspase-1-mediated IL-1β maturation,
whereby PAMPs, such as LPS, provide ‘signal I’ and diverse
agents (such as ATP and nigericin) act as ‘signal II’. Generally,
signal I induces the transcriptional expression of NLRP3 and IL-
1β. Additionally, signal I can non-transcriptionally prime NLRP3
by stimulating its deubiquitylation15. This process is dependent
on mitochondrial ROS and can be inhibited by antioxidants.
Signal II induces processing of pro-IL-1β to the p17 active form,
which is then released into the extracellular space.
In contrast to other inﬂammasomes, the NLRP3 inﬂamma-
some is activated in response to a wide variety of stimuli
including pore-forming toxins, nigericin, maitotoxin, and vali-
nomycin, as well as the P2X7 channel activator ATP, uric acid,
silica crystals, and the widely used adjuvant aluminium hydro-
xide1. A mechanism for NLRP3 inﬂammasome activation that
unites all signal II stimuli has yet to emerge. One intriguing
possibility is that the cellular changes sensed by NLRP3 may
converge on a common regulatory mechanism, for example
modulation of post-translational modiﬁcations (PTMs), such as
phosphorylation, ubiquitylation or sumoylation. Protein mod-
iﬁcation by small ubiquitin-like modiﬁer (SUMO) allows the
dynamic regulation of proteins as most substrates undergo a
constant turnover of SUMO conjugation and de-conjugation16.
Similar to ubiquitylation, sumoylation is regulated by a specia-
lised set of activating (E1), conjugating (E2) and ligating (E3)
enzymes, and is reversed by speciﬁc isopeptidases referred to as
sentrin/SUMO-speciﬁc proteases (SENPs)16,17. The three SUMO
proteins (SUMO-1, SUMO-2 and SUMO-3) can be covalently
conjugated to proteins as a single moiety (SUMO-1) or as poly-
meric SUMO chains (SUMO-2 and SUMO-3). Sumoylation is
essential for maintaining cell homeostasis, and as such is impli-
cated in many cellular processes including cellular stress response,
DNA replication and repair, apoptosis and inﬂammation18.
Although the majority of sumoylated proteins are localised to the
nucleus, a number of cytoplasmic, mitochondrial and membrane-
associated targets have recently been identiﬁed19–21. Sumoylation
of substrates preferentially occurs on a lysine residue in the
canonical SUMO consensus motif ψKx(D/E), in which ψ is a
large hydrophobic residue and x is any amino acid followed by an
acidic residue16,22. The hydrophobic and acidic residues stabilise
the interaction between the substrate and the E2 enzyme,
UBC923.
Here we demonstrate that conjugation of SUMO negatively
regulates the NLRP3 inﬂammasome, implicating sumoylation as a
fundamental post-translational mediator of innate immune sig-
nalling. We show that NLRP3 is sumoylated at multiple sites, and
identify MAPL as a SUMO E3 ligase responsible for
NLRP3 sumoylation. Accordingly, depletion of MAPL in mouse
bone marrow-derived macrophages (BMDMs) signiﬁcantly
enhances NLRP3 inﬂammasome formation and activity. In
addition, using nuclear magnetic resonance (NMR) and in vitro
sumoylation assays we identify lysine (K) 689 as a sumoylation
site of NLRP3. Mutation of this K689 residue results in hyper-
activation of NLRP3. Furthermore, we show that desumoylation
of NLRP3 by the desumoylase enzymes SENP6 and SENP7
controls NLRP3 inﬂammasome activation in BMDMs. Consistent
with the notion that SENP-mediated desumoylation contributes
to full activation of the NLRP3 inﬂammasome, we ﬁnd that
depletion of these SENPs attenuates inﬂammasome formation
and downstream signalling. Together our data demonstrate that
NLRP3 is regulated in a SUMO-dependent manner, and that
desumoylation of NLRP3 by SENP6 and SENP7 contributes to
full inﬂammasome activation.
Results
NLRP3 is sumoylated in vivo. Deregulated activation of NLRP3
is associated with auto-inﬂammatory disorders characterised with
excessive production of IL-1β24. It is presently unclear how the
NLRP3 inﬂammasome is kept silent under base-line conditions.
Bioinformatics analysis of NLRP3 using four independent com-
putational programmes to detect sumoylation sites (SUMO-
plotTM Analysis Programme (Abgent), JASSA25, GPS-SUMO26,
and Ron Hay’s SUMO motif search tool) identiﬁed six potential
SUMO-conjugation consensus motifs, ﬁve of which are evolu-
tionarily conserved (red boxes) from mouse to man (Fig. 1a, b).
In contrast to NLRP3, no such evolutionarily conserved SUMO
consensus motifs were identiﬁed in ASC and pro-caspase-1. In
addition to SUMO consensus motifs, we also identiﬁed a putative
SUMO-interaction motif (SIM) within the LRR of mouse
(Q8R4B8, SIM: amino acids 797–800 (LVEL) and human NLRP3
(Q96P20, SIM: amino acids 800–803 (LVEL)). This was the only
putative SIM that was predicted by both JASSA and GPS algo-
rithms. Although this putative SIM is evolutionarily conserved it
has a relatively low probability score.
To test whether NLRP3 is regulated by sumoylation in vivo, we
immunoprecipitated NLRP3 from cellular extracts following
denaturing conditions, avoiding the isolation of protein complexes.
We used the previously described Nlrp3−/− BMDMs that re-
express NLRP3 from a transgene (Nlrp3−/−.reconNLRP3, subse-
quently referred to as N1-8)15. The N1-8 macrophages
express FLAG-tagged NLRP3 at a level comparable
to that present in un-induced wild-type (WT) macrophages (basal
level)15. Immunoblotting of the NLRP3 immunoprecipitates using
SUMO-2/-3 speciﬁc antibodies identiﬁed high apparent molecular
weight NLRP3 species corresponding to sumoylated NLRP3
(Fig. 1c). No such signals were detected in immunoprecipitates of
Nlrp3−/− BMDMs, indicating that the detected bands were speciﬁc
for sumoylated NLRP3. To test whether NLRP3 is also sumoylated
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in human cells, we transfected human NLRP3 into HEK293T cells,
and conjugation of endogenous SUMO-2/-3 to NLRP3 was
conﬁrmed by immunoprecipitation of NLRP3 (Fig. 1d). Treatment
with the non-selective isopeptidase inhibitor PR-619, which also
blocks SUMO deconjugating enzymes, signiﬁcantly enhanced the
appearance of sumoylated NLPR3 (Fig. 1d, compare lanes 3 with 4).
Conjugation of SUMO-2/-3 to human NLRP3 was also conﬁrmed
by reciprocal immunoprecipitation of HA-tagged WT SUMO-3 or
a mutant form of SUMO-3 (SUMO-3ΔGG) that cannot be
conjugated to substrates due to deletion of the critical C-terminal
di-Gly motif of SUMO-3 (Fig. 1e). Under these conditions, NLRP3
was readily immunoprecipitated with WT SUMO-3, but not with
SUMO-3ΔGG (Fig. 1e), demonstrating the selectivity of the
puriﬁcation and SUMO conjugation. Consistent with a mono-
sumoylation event, we observed NLRP3 species that migrated
approximately 10 kDa above unmodiﬁed NLRP3. In addition to
mono-sumoylated NLRP3, higher molecular weight smears of
NLRP3 were also observed, indicating the presence of polymeric
SUMO-3 chains or co-modiﬁcation with SUMO and ubiquitin (Ub)
chains (Fig. 1e, lane 3). Taken together, these results indicate
that NLRP3 is sumoylated in murine macrophages and human
cells.
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Signal II triggers loss of sumoylation of NLRP3. Since NLRP3 is
modiﬁed by SUMO under unstimulated conditions we investi-
gated whether NLRP3-activating stimuli (signal II) alters the
sumoylation state of NLRP3. Accordingly, we found that treat-
ment with the bacterial toxin nigericin induced notable reduction
of sumoylated NLRP3 (Fig. 2a). Under the same conditions,
NLRP3 was also less ubiquitylated, as previously reported15,
suggesting that the activation signal triggers reduction in both
ubiquitylated and sumoylated NLRP3. Of note, nigericin-
mediated reduction in sumoylation of NLRP3 was selective as
other sumoylated proteins, such as RanGAP1, remained sumoy-
lated under the experimental conditions (Fig. 2a). Moreover,
there was no apparent change in the overall smearing pattern of
the total SUMO-2/-3 proteome, ruling out the possibility that
nigericin stimulates a reduction in sumoylation non-selectively.
We next determined the sumoylation status of endogenous
NLRP3 in WT BMDMs. To visualise the interaction between
endogenous NLRP3 and SUMO-2/-3 in intact WT BMDMs, we
applied in situ proximity ligation assay (PLA). In addition to
detecting protein-protein interactions27 and inﬂammasome
activation28–30, this method has been described for the study of
PTMs, speciﬁcally sumoylation31. Using primary antibodies
against NLRP3 and SUMO-2/-3, which in turn were recognised
by oligonucleotide-coupled secondary antibodies, we obtained
discrete proximity labelling of NLRP3 and SUMO-2/-3 under
unstimulated conditions (Fig. 2b, upper panel). Likewise, distinct
NLRP3-SUMO-2/-3 PLA signals were detected upon LPS
priming, which were comparable to the ones of unstimulated
WT BMDMs (Fig. 2b). Of note, priming with LPS did not
inﬂuence NLRP3 sumoylation (Supplementary Fig. 1a). Impor-
tantly, no such PLA signals were observed in Nlrp3−/− control
BMDMs, demonstrating the suitability of the PLA to detect
NLRP3-SUMO-2-/3 interactions. Interestingly, treatment with
nigericin and ATP signiﬁcantly reduced proximity labelling of
NLRP3 and SUMO-2/-3, which is entirely consistent with our
biochemical analysis (Fig. 2a). While proximity labelling of
NLRP3 and SUMO-2/-3 was markedly reduced, general expres-
sion of NLRP3 and SUMO-2/-3 was unaffected by the addition of
LPS and nigericin, as determined by immunoﬂuorescence
staining of the individual proteins (Supplementary Fig. 1b). As
expected, PLA with antibodies against NLRP3 and the inﬂamma-
some adapter component ASC revealed that inﬂammasome
complexes were absent under base-line conditions, and speciﬁ-
cally formed upon treatment with LPS and nigericin or ATP
(Fig. 2b and Supplementary Fig. 1c). Together, our data indicate
that inﬂammasome formation occurs in concordance with loss of
sumoylation of NLRP3, supporting the working hypothesis that
sumoylation impedes NLRP3 complex formation.
MAPL suppresses inﬂammasome activation. To study SUMO-
mediated regulation of NLRP3, we next identiﬁed a SUMO E3
ligase that modiﬁes NLRP3. While the SUMO E2 enzyme can
directly interact with a SUMO consensus motif present in sub-
strates, this interaction is insufﬁcient for an efﬁcient SUMO
transfer in vivo and needs to be stabilised either by additional E2
interactions or by E3 ligases16. Particularly, E3 ligases interact with
the substrate and the charged E2 enzyme to catalyse the discharge
of the thioester-bound SUMO from the E2 enzyme to the sub-
strate. Although the majority of SUMO E3 ligases identiﬁed are
nuclear localised, a mitochondria-localised SUMO E3 ligase has
recently been identiﬁed, mitochondrial-anchored protein ligase
(MAPL/MUL1). MAPL is known to play a role in the control of
mitochondria morphology and localisation32,33. In addition,
MAPL is involved in the modulation of innate immune defence
against viruses by sumoylating and inhibiting DDX5834,35. Given
that NLRP3 can also localise to mitochondria36–38, we tested the
ability of MAPL to bind to and sumoylate NLRP3. Reciprocal
immunoprecipitation assays revealed that NLRP3 interacted with
MAPL (Fig. 3a, b). Consistent with the notion that MAPL can
function as the SUMO-E3 ligase for NLRP3, we found that WT
MAPL sumoylated NLRP3 (Fig. 3c). In contrast, a SUMO-E3
deﬁcient MAPL mutant (MAPLC399A), carrying a point mutation
in the zinc coordinating cysteine of the RING domain, failed to
sumoylate NLRP3. These results indicate that MAPL sumoylates
NLRP3 in a RING-ﬁnger dependent manner.
To test whether MAPL interacts with NLRP3 at endogenous
levels, we applied PLA in WT BMDMs using primary antibodies
against MAPL and NLRP3. In unstimulated as well as in LPS-
treated WT BMDMs, we obtained discrete proximity labelling of
MAPL and NLRP3 (Figs. 3d and 4a), corroborating the notion that
the two proteins are in close proximity. Importantly, no such signals
were observed in Nlrp3−/− BMDMs or upon knockdown of Mapl
(Figs. 3d and 4a). Excitingly, treatment with nigericin almost
completely abolished MAPL/NLRP3 proximity signals (Figs. 3d and
4a). This may be due, at least in part, to depletion of MAPL because
nigericin treatment caused a decrease in MAPL staining, as
visualised by conventional immunoﬂuorescence (Supplementary
Fig. 2). This suggests that inﬂammasome-activating stimuli disrupt
the interaction between MAPL and NLRP3, thus ceasing MAPL-
mediated sumoylation of NLRP3.
To test whether MAPL is indeed required for the association of
endogenous SUMO and NLRP3, we depleted Mapl from WT
BMDMs by RNAi. Although knockdown efﬁciency was approxi-
mately 50% (Supplementary Fig. 3a, b), a considerable reduction in
MAPL/NLRP3 proximity signals was observed, which served as an
additional control (Fig. 4a, top panel). RNAi-mediated depletion of
Mapl dramatically reduced the association between NLRP3/SUMO-
2/-3, as seen by the reduced proximity signal in unstimulated and
LPS-treated WT BMDMs (Fig. 4a, middle panel).
Given the reduced association between NLRP3 and SUMO-2/-
3 following Mapl depletion, we next tested whether depletion of
Mapl enhanced inﬂammasome formation using PLA28–30.
Fig. 1 NLRP3 is modiﬁed by SUMO-2/-3. a Schematic representation of the six predicted SUMO-conjugation motifs (ψKXE) and SUMO-interaction motif
(SIM) in the NLRP3 protein. b Left-hand side, details of the SUMO-conjugation motifs and summary of prediction software scores. Analysis using R. Hay
website provides motif type (S= strict and R= relaxed). Conservation of the predicted SUMO conjugation motifs between mouse and human NLRP3 are
depicted underneath. Red boxes indicate evolutionary conserved sites, grey boxes indicate sites that are only present in humans. Right-hand side, structural
prediction of NLRP3 depicting the identiﬁed SUMO motifs. The acceptor lysines shown in (a) are highlighted as red sticks. Note, K88 and K204 are in
ﬂexible loops and hence are not part of the model. The structural prediction of NLRP3 was created using PHYRE2. c Sumoylation of NLRP3 in murine Nlrp3
−/− BMDMs and N1-8 BMDMs that were reconstituted with FLAG-tagged NLRP3 (N1-8). NLRP3 was immunoprecipitated and the presence of the
indicated proteins was evaluated using the indicated antibodies. For this and all subsequent immunoblots, representative immunoblots are shown from at
least three independent experiments. d Sumoylation of NLRP3 in HEK293T cells expressing FLAG-tagged human NLRP3 in the presence and absence of PR-
619. NLRP3 was immunoprecipitated and the presence of the indicated proteins was evaluated using the indicated antibodies. e Sumoylation of NLRP3 in
HEK293T cells transfected with FLAG-tagged human NLRP3 and HA-SUMO-3 or SUMO3ΔGG (non-conjugatable) control. Proteins covalently bound to
HA-SUMO-3 were puriﬁed under denaturing conditions using HA-resin. The presence of the indicated proteins was evaluated by immunoblotting
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Consistently, we found that depletion of Mapl indeed enhanced
oligomerisation of ASC (Supplementary Fig. 3c) and the
formation of inﬂammasome complexes (Fig. 4a, lower panel).
Of note, PLA detects hundreds of co-localisation dots28–30
instead of the characteristic ASC speck. Because PLA is a PCR-
based method, it is probably more sensitive than conventional
antibody-based confocal microscopy, and hence may also detect
pre-speck complexes.
Enhanced inﬂammasome formation upon Mapl deleption
implies that the NLRP3 inﬂammasome will be more active.
Therefore, we next deﬁned the contribution of MAPL in
regulating inﬂammasome activity. To rule out any transcriptional
involvement of sumoylation in NLRP3 activation, we used the
N1-8 BMDMs in which the transcriptional induction of Nlrp3
does not depend on priming15. To further eliminate any
transcriptional involvement, we used a short 10 min incubation
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with LPS, which primes the NLRP3 inﬂammasome by a non-
transcriptional mechanism15 (Fig. 4b). In agreement with the
notion that MAPL regulates NLRP3 under physiological condi-
tions, we found that RNAi-mediated depletion of Mapl in N1-8
BMDMs signiﬁcantly enhanced nigericin-induced activation of
caspase-1 and production of IL-1β (Fig. 4c, d). In contrast,
depletion of Mapl had no effect on AIM2-mediated activation of
caspase-1 in response to cytoplasmic DNA (Fig. 4c, lanes 9–12).
As knockdown of Mapl selectively affects the NLRP3 inﬂamma-
some, these results support the notion that NLRP3, but not AIM2
or common components such as ASC and caspase-1, is subject to
SUMO-mediated regulation by MAPL.
Mutation of sumoylated K residues causes hyperactive NLRP3.
To functionally test the role of the putative SUMO-conjugation
consensus motifs of NLRP3, we mutated the surface exposed
SUMO-acceptor lysines (K) of each motif and analysed the ability
of these mutants to activate caspase-1. To this end, we made use
of a previously established HEK293T cell line, stably expressing
ASC and caspase-1 (293T-ASC-caspase-1 cells)39. As previously
reported, expression of WT NLRP3 stimulated activation of
caspase-1 in these cells (Fig. 5a–c). Intriguingly, we found that
mutating individual SUMO conjugation consensus sites in iso-
lation slightly enhanced the ability of NLRP3 to activate caspase-
1, ranging from 1.3-fold to 1.7-fold when compared to WT
NLRP3 (Fig. 5a). Mutating all six SUMO acceptor K of NLRP3
(NLRP36K>R) further enhanced activation of caspase-1 (Fig. 5b,
c), while mutating the SIM (LVEL to AAEA) reproducibly low-
ered the ability of NLRP3 to activate caspase-1 (Fig. 5c). The
potency of NLRP36K>R to activate caspase-1 was comparable to
that of reported CAPS disease mutants, such as NLRP3R260W,
NLRP3E690K and NLRP3E692K (Fig. 5b, c and Supplementary
Fig. 4a), which served as controls40.
Residues of the SUMO consensus motifs interact directly with
the SUMO E2 ligase, UBC923,41. To test whether the predicted
SUMO consensus motifs indeed interact with UBC9, we
performed NMR with UBC9 and an NLRP3 peptide stretch
containing the SUMO consensus motif surrounding K689.
Increasing NMR chemical shift perturbation (CSP) was induced
by increasing peptide:UBC9 molar ratios of the WT peptide
(Fig. 5d). WT peptide induced signiﬁcant CSP on residues L94,
D127, A129 and Y134 (Fig. 5d). Substitution of the target K to R
(K689R peptide) lead to weak CSP, indicating reduced binding to
UBC9 (Fig. 5d). This result suggests that the binding mode is
similar to that of other ψKx(D/E) motifs that we examined
previously42 (depicted model Supplementary Fig. 4b). We next
performed an in vitro conjugation assay to determine if K689 can
be modiﬁed by SUMO. As expected, the peptide corresponding to
the WT NDSM was modiﬁed by SUMO-1 and SUMO-3, whereas
the peptide containing the K > R substitution was not (Fig. 5e).
Together, these data suggest that SUMO can be conjugated to
K689 of NLRP3. Mutating K689 to R in full length NLRP3
(NLRP3K689R), like mutating other SUMO conjugation consensus
sites in isolation, had no effect on the overall protein levels as well
as sumoylation or ubiquitylation pattern of NLRP3 in vivo, likely
due to additional modiﬁcations occurring at alternative sites
(Supplementary Fig. 4c). This is in slight conﬂict to a previous
in vitro assay, suggesting that a K689R NLRP3 mutant is less
polyubiquitylated compared to WT NLRP3 (see Discussion)43. Of
note, mutation of single residues reported in CAPS disease
mutants (NLRP3R260W, NLRP3E690K and NLRP3E692K) did not
reduce the overall sumoylation smearing pattern on NLRP3
(Fig. 5f, and Supplementary Fig. 4d). However, consistent with
the notion that NLRP3 is sumoylated at multiple sites, we found
that substitution of all six K residues to R (NLRP36K>R)
diminished NLRP3 sumoylation by 50% when compared to
WT NLRP3 (Fig. 5f). Importantly, mutating these SUMO
acceptor K residues did not affect overall ubiquitylation of
NLRP3 (Fig. 5f and Supplementary Fig. 4c). Accordingly, WT
NLRP3 and NLRP36K>R were ubiquitylated to similar extent. As
sumoylation was not completely abrogated, our data suggest that
alternative K residues can also serve as SUMO acceptors when the
canonical sites are mutated. Conversely, mutation of the putative
SIM of NLRP3 (NLRP3SIM-mut) caused enhanced sumoylation of
NLRP3 (Fig. 5f).
SENP6 and 7 regulate NLRP3 activation and IL-1β secretion.
Next, we assessed the contribution of SUMO de-conjugating
enzymes to the regulation of NLRP3. We found that RNAi-
mediated knockdown of Senp6 and Senp7 reproducibly sup-
pressed autocatalytic caspase-1 maturation and secretion in
response to ATP (Fig. 6a). Under the same conditions, depletion
of Senp6 and Senp7 had no effect on AIM2-mediated activation of
caspase-1 in response to cytosolic DNA (Fig. 6a, lane 9–16).
Partial depletion of Senp6 and/or Senp7 (~50% knockdown) also
suppressed NLRP3-mediated activation and release of caspase-1
in response to nigericin in N1-8 as well as WT BMDMs (Fig. 6b,
and Supplementary Fig. 5a–c). While partial RNAi-mediated
depletion of Senp6 and Senp7 reduced ATP and nigericin-induced
caspase-1 activation, knockdown of other members of the SENP
protein family did not signiﬁcantly modulate the ability of NLRP3
to activate caspase-1 (Fig. 6b, and Supplementary Fig. 5a). Con-
sistent with the notion that SENP7 contributes to activation of the
NLRP3-inﬂammasome, we found that depletion of Senp7 reduced
ASC oligomerisation, caspase-1 activation/release, as well as IL-1β
processing/release (Fig. 6c–e, and Supplementary Fig. 5b, c and
d). Taken together, the observation that knockdown of Senp6 and
Senp7, which belong to the same sub-class of the SENP family of
isopeptidases, selectively suppresses NLRP3-dependent activation
of caspase-1 strongly suggests that the NLRP3 inﬂammasome is
regulated in a SUMO-dependent fashion.
Discussion
The NLRP3 inﬂammasome plays a key role in host defence, and is
activated by numerous pathogen-associated and danger-
Fig. 2 Signal II triggers depletion of sumoylated NLRP3. a Nigericin treatment results in the reduction of sumoylated NLRP3. HEK293T cells expressing
FLAG-NLRP3 were stimulated with nigericin for the indicated time points. FLAG-NLRP3 immunoprecipitates were analysed for sumoylation (upper panel)
and ubiquitylation (middle panel). SUMO and ubiquitin smears were quantiﬁed using Image Lab Software (Bio-Rad) and the modiﬁcation normalised to
total immunoprecipitated NLRP3. Graphs represent fold change compared to untreated cells. The effect of nigericin stimulation on global SUMO-2/-3
levels was determined by immunoblot analysis of total cell lysates. The data depict representative immunoblots of three independent experiments.
b Endogenous NLRP3 interacts with SUMO-2/-3, but the interaction is lost upon NLRP3 activation by treatment with LPS and nigericin (left panel) or ATP
(middle panel). Immortalised WT or Nlrp3−/− murine BMDMs were left untreated, primed with LPS for 4 h or treated with LPS (4 h) followed by 30min
with nigericin or 20min with ATP. Cells were ﬁxed and proximity ligation assay (PLA) was performed using α-NLRP3 and either α-SUMO-2/-3 (upper
panel) or α-ASC antibodies (lower panel), as indicated. Representative confocal microscopy images are shown for each condition, which was repeated at
least three times, except for ATP (n= 1). Scale bar, 10 µm
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associated molecular patterns1,44. Several danger signals such as
ATP, alum hydroxide, silica crystals, urea crystals, nigericin, and
infections with bacteria, viruses, and fungi activate the NLRP3
inﬂammasome. How NLRP3 recognises these different ligands
and whether a common signal converges downstream of PAMPs
and DAMPs to activate NLRP3 has been a longstanding question
in the ﬁeld. Here, we show that NLRP3 is sumoylated, and that
NLRP3-activating stimuli result in the removal of SUMO from
NLRP3. Several lines of evidence support the notion that NLRP3
is regulated by sumoylation. First, under steady-state conditions
NLRP3 associates with the SUMO E3 ligase MAPL and is
sumoylated. Second, upon activation of the NLRP3 inﬂamma-
some the interaction between NLRP3 and MAPL is disrupted
and NLRP3 is de-sumoylated. Third, depletion of MAPL
results in enhanced inﬂammasome formation and activity.
Fourth, an NLRP36K>R mutant that is less sumoylated is sig-
niﬁcantly more potent in activating caspase-1. Fifth, NLRP3K689R,
which carries a mutation of the evolutionarily conserved SUMO
acceptor K689, and cannot be sumoylated in vitro in an UBC9-
dependent manner, is hyperactive in driving caspase-1 cleavage.
Finally, reduced de-sumoylation of NLRP3 through the deletion
of SENPs signiﬁcantly impairs its ability to drive ASC oligo-
merisation, caspase-1 activation and production of biological
active IL-1β.
While the desumoylase enzymes SENP6 and SENP7 reverse
SUMO-mediated inactivation of NLRP3, MAPL-mediated
sumoylation of NLRP3 suppresses inﬂammasome formation.
Accordingly, depletion of the SUMO E3 ligase MAPL enhances
caspase-1 activation and the release of bioactive IL-1β in response
to NLRP3 inﬂammasome triggers. Conversely, depletion of the
SENP6 and SENP7 impairs inﬂammasome formation, caspase-1
activation and IL-1β release. MAPL-mediated regulation of IL-1β
production is speciﬁc to the NLRP3 inﬂammasome as depletion
of MAPL, SENP6 or SENP7 has no effect on the activity of the
AIM2 inﬂammasome. Consistent with the notion that sumoyla-
tion of NLRP3 inhibits inﬂammasome activation, we ﬁnd that
treatment with nigericin and ATP results in loss of SUMO
conjugation to NLRP3. Unlike other PTMs, SUMO appears to
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regulate protein function through a constant cycle of SUMO-
conjugation and de-conjugation. Therefore, SUMO-modiﬁcation
may be removed from proteins either by activating desumoylase
enzymes or inhibiting SUMO-conjugation, under which case
constitutively active SUMO peptidases would ‘clean’ such pro-
teins of SUMO adducts. Intriguingly, Listeria monocytogenes and
Streptococcus pneumonia reportedly impair host-sumoylation
during infection by degrading the SUMO E2 ligase, UBC945.
While UBC9 degradation may be beneﬁcial for efﬁcient infection,
pathogen-induced depletion of UBC9 may be recognised through
the concomitant accumulation of non-sumoylated NLRP3, which
is known to be essential for inﬂammasome activation in response
to both L. monocytogenes11 and S. pneumonia46.
In addition to sumoylation, NLRP3 is also regulated in a ubi-
quitin-dependent, nitric oxide-dependent and phospho-
dependent manner, emphasising the importance of NLRP3
regulation15,47–51. In unstimulated cells, NLRP3 is inhibited by
K63-linked and K48-linked poly-ubiquitylation, and de-
b
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ubiquitylated by BRCC3 upon stimulation47. Furthermore, a
number of Ub E3 ligases have been identiﬁed that promote K48-
linked poly-ubiquitylation and degradation of NLRP3, such as
ARIH2, FBXL2, MARCH7 and TRIM3143,52–54. Given that
NLRP3 is inhibited by both SUMO and ubiquitin this raises the
intriguing possibility of interplay between these two PTMs. One
possibility is that SUMO and ubiquitin work synergistically to
keep NLRP3 in an inactive conﬁguration, or by altering the
subcellular localisation of NLRP3, preventing association with the
adapter ASC. According to the latter hypothesis, we noticed that
PLA detects sumoylated NLRP3 in the nucleus. Thus, sumoylated
NLRP3 might be shuttled into the nucleus by SUMO-binding
proteins. Further, NLRP3 may be antagonistically modiﬁed with
either SUMO or ubiquitin, as has previously been observed for
NF-kB55. Recently, K689 within NLRP3 has been postulated to be
a target for ubiquitylation in vitro43. Our study demonstrates that
K689, which is located within a bioinformatically predicted
SUMO consensus motif, is targeted by SUMO in an UBC9-
dependent manner. This suggests that modiﬁcation at this residue
is crucial to prevent aberrant activation of NLRP3. Intriguingly,
the defect in sumoylation of NLRP3 at K689R (NLRP3K689R)
phenocopies reported mutations identiﬁed in CAPS patients
(NLRP3E690K and NLRP3E692K; Infevers registry). Both these
mutations cause constitutive inﬂammasome activation and IL-1β
secretion56–58. As both map to the predicted negatively charged
amino acid-dependent SUMO motif (NDSMs) surrounding
K689, an interesting possibility is that these mutants affect proper
binding to UBC9, thereby causing deregulation of
NLRP3 sumoylation and activation.
Uncontrolled NLRP3 inﬂammasome activation underlies sev-
eral human diseases, including genetically inherited auto-
inﬂammatory conditions as well as chronic-inﬂammatory
diseases44,59. Thus, activation of NLRP3 needs to be tightly
controlled. It is now apparent that NLRP3 activity is regulated
through the combined effects of various PTMs, including
sumoylation. These modiﬁcations are likely to ﬁne-tune NLRP3
activation to enable a rapid response to diverse danger signals.
Accordingly, different NLRP3 pro-inﬂammatory insults may
result in differential responses, depending on which PTM is
alleviated. The identiﬁcation of a sumoylation/de-sumoylation
equilibrium that regulates NLRP3, constitutes an important
advance in the ﬁeld of inﬂammation with therapeutic potential
because NLRP3 plays pivotal roles in many inﬂammatory dis-
orders. As de-sumoylation is critical for full NLRP3 activation,
targeting SENPs may offer new opportunities for treating
inﬂammatory diseases that are caused by aberrant activation of
the NLRP3 inﬂammasome, such as type-II diabetes, gout, and
Alzheimer’s disease. Current therapies are solely based on neu-
tralising pro-inﬂammatory cytokines in the circulation60, and
since aberrant inﬂammasome activation also results in pyroptosis,
inhibiting the removal of SUMO from NLRP3 by targeting SENPs
may provide an alternative approach for the treatment of
inﬂammatory diseases.
Methods
Reagents, constructs and antibodies. Ultra-pure EK-LPS (tlrl-peklps), ATP (tlrl-
atp) and nigericin (tlrl-nig) were from Invivogen and PR-619 (SI9619) from
LifeSensors. The pC1-Hs-Nlrp3-FLAG and pC1-Hs-Nlrp3R260W-FLAG vectors were
kindly provided by Veit Hornung. The four 5’ K > R mutations in the 6K > R
mutant of NLRP3 were introduced by replacing WT fragment between internal
restriction sites, KpnI and BglII with a synthetic fragment containing the mutations
(GeneArt, LifeTechnologies). The additional K652R and K689R mutants were
introduced by site-directed mutagenesis. To create pC1-Hs-Nlrp3-ΔSIM-FLAG,
WT NIrp3 was digested with BglII and EcoRI and the fragment replaced with a
synthetically generated fragment containing the mutations (GeneArt, Life-
Technologies). The pEF-HA-SUMO3 was cloned from pcDNA3-HA-SUMO3
kindly provided by Ron Hay. The pEF-HA-SUMO3-ΔGG construct was generated
by PCR ampliﬁcation from pEF-HA-SUMO3 using primers listed in Supplemen-
tary Table 1. Mapl cDNA was PCR ampliﬁed from pOTB7-Mapl (BioCat) and
cloned into pcDNA5.5-2xHA/2xSTREP using KpnI and EcoRV sites. To generate a
catalytically inactive form of MAPL, cysteine 339 was mutated to an alanine using
site-directed mutagenesis (primers listed in Supplementary Table 1). All constructs
used in this study were veriﬁed by DNA sequencing (Euroﬁns Genomics). The
following antibodies were used at a dilution of 1:1000 for western blot analysis: α-
caspase-1 full length and p20 (Casper-1, mouse, Adipogen), α-caspase-1 full length
and p20 (Bally-1, human, Adipogen), α-NLRP3 (Cyro-2, Adipogen), α-ASC
(AL117, Adipogen), α-IL-1β (AF-401-NA, R&D), α-SUMO-2/-3 (BML-PW9465,
Enzo), α-pan-Ub (Z0458, Dako), α-RanGAP1 (19C7, LifeTechnologies), α-HA
(3F10, Roche), α-GFP (JL-8, Clontech), α-α-tubulin (T-9026, Sigma), α-HSP90 (H-
114, Santa Cruz).
Tissue culture, RNA interference and transfections. Immortilised WT, Nlrp3
knockout (KO) and N1-8 BMDMs and HEK293T expressing ASC and caspase-1
(AC) cell lines were kindly provided by Emad Alnemri and were described pre-
viously15. HEK293T cells were obtained from ATCC. All cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% foetal
bovine serum (Gibco) and cultured at 37 °C under 10% CO2. Cell lines were tested
for mycoplasma using MycoAlertTM Mycoplasma detection kit (Lonza). siRNAs
were ordered as siGENOME SMARTpools (Dharmacon). For RNAi of mouse,
Senp6 an optimised pool was used [Cat: # D-062052-01 & # D-062052-03]. All
siRNA experiments were performed using 50 nM siRNA. The BMDMs were
electroporated using Neon Transfection System (LifeTechnologies) according to
manufacture instructions (settings: 1000 V, 40 ms, 2 pulses). For DNA transfec-
tions Genejuice Transfection Reagent (Merck Millipore) and Opti-MEM (Life-
Technologies) were used according to manufacture instructions.
Inﬂammasome activation. Cells were treated 48–60 h post-siRNA in 24-well
plates. For short priming, cells were treated with 500 ng/ml of ultrapure LPS for
10 min prior to the addition of the activation stimuli. For longer priming cells were
treated for 4 h with LPS prior to addition of activation stimuli. To stimulate the
AIM2 inﬂammasome 1 μg/ml of pcDNA3.1 was transfected using Lipofectamine
2000 (LifeTechnologies) for 3 h. For NLRP3 inﬂammasome activation cells were
treated with 10 μM nigericin for 90 min or with 5 mM ATP for 60 min unless
otherwise stated.
Western blot analysis. Following inﬂammasome stimulations cell supernatants
were collected, centrifuged at 4 °C at 1000 rpm and lysed in 6 × SDS loading dye.
The cells remaining on the plate were lysed in 1× SDS loading dye, passed through
0.8 ml columns (Pierce) to shred genomic DNA. Supernatant or cellular lysates
Fig. 4 MAPL-mediated sumoylation of NLRP3 suppresses inﬂammasome activation. a Depletion of MAPL reduces the association between NLRP3 and
SUMO-2/-3 and increases the interaction between NLRP3 and ASC. Immortalized WT BMDMs were transfected with non-targeting or Mapl-speciﬁc
siRNAs. After 48 h, cells were left untreated, primed with LPS for 4 h or treated with LPS (4 h) followed by 30min with nigericin. PLA was performed using
α-NLRP3 and either α-MAPL (upper panel), α-SUMO-2/-3 (middle panel) or α-ASC antibodies (lower panel), as indicated. Representative confocal
microscopy images are shown for each condition. Scale bar, 10 µm. The number of ﬂuorescent spots per cell was quantiﬁed for 50 cells. The average of
duplicate counts is represented on the right-hand side of the microscopy images. Circles represent individual data points and error bars represent ±SD.
Data were analysed using two-way ANOVA multiple comparison test **P < 0.01, ***P < 0.001. b Schematic diagram of the experimental procedure
performed in c. c Activation and release of caspase-1 under the indicated conditions was evaluated by western blot. N1-8 macrophages were transfected
with non-targeting or Mapl-speciﬁc siRNAs and primed with LPS (10min for caspase-1 or 4 h for IL-1β). Cells were subsequently stimulated with nigericin
or cytoplasmic DNA. Cleaved caspase-1 (p20 band) was quantiﬁed using Image Lab Software (Bio-Rad). d IL-1β levels in the cell supernatant were
measured by enzyme-linked immunosorbent assay (ELISA). Individual data points (circles) of three independent experiments are presented as fold change
compared to Ctrl N1-8 BMDMs (non-targeting siRNA). Grey bar is the mean ± SEM. **P < 0.01; two-tailed Student’s t-test on log2-transformed data
comparing nigericin treated BMDMs transfected with Mapl-speciﬁc siRNA to Ctrl BMDMs
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Fig. 5 Mutation of SUMO acceptor lysines results in hyperactive NLRP3. a–c Immunoblot analysis of inﬂammasome components (caspase-1, ASC and
NLRP3) in cell lysates of HEK239T cells, stably expressing ASC and caspase-1, transfected with the indicated proteins. Caspase-1 maturation (p20 band)
was evaluated by western blot. d NMR analysis of the interaction between UBC9 and WT and K689R mutant NLRP3 peptides. Overlays of the expanded
regions of 1H-15N HSQC spectra of free UBC9 (red) and UBC9 in complex with the peptide at 8:1 molar ratio (green). Only peaks with signiﬁcant chemical
shift perturbation are labelled with their assignments. e In vitro sumoylation assays of WT and mutant peptides using SUMO-1 or GST-fusion SUMO-3.
f HEK293T cells were transfected with plasmids expressing the indicated proteins and FLAG-NLRP3 immunoprecipitates were evaluated for sumoylation
and ubiquitylation. The modiﬁcations were quantiﬁed using Image Lab Software (Bio-Rad) and normalised to total immunoprecipitated NLRP3. The data of
three independent experiments are presented as log2-transformed fold changes of the mutants compared to WT NLRP3. Line represents the mean. *P <
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samples were boiled for 5 min before separating by SDS-PAGE using NuPAGE
Novex 4–12% Bis-Tris 1.0 mm 20 well pre-cast midi protein gels (Life Technolo-
gies) in MES or MOPS buffer, respectively. Uncropped western blot images are
included in Supplemental Fig. 6.
Real-time quantitative RT-PCR. RNA was isolated using RNeasy mini kit (Qia-
gen) and cDNA synthesised using QuantiTech reverse transcription (Qiagen).
Quantitative real-time (RT)-PCR reactions were performed using the FAM-MGB
Taqman gene expression probe for SENP6 [Cat: #mm01148533_m1], SENP7 [Cat:
#mm01146706_m1] and MAPL/MUL1 [Cat: #mm00503326_m1] (Applied Bio-
systems). Relative mRNA levels were calculated after normalisation to Actin [Cat:
#mm00607939_s1] using the ΔCt method.
Peptide synthesis. In glass peptide synthesis vessel, 100 mg of the chlorotrityl
resin (Iris Biotech GmbH) was activated in dry dichloromethane (DCM, POCH)
for an hour, followed by washing and addition of 3 eq of Fmoc-Asp(tBu)-OH
activated with 6eq of DIPEA (Sigma Aldrich) in dry DCM prior to loading.
Reaction was carried out for 3 h (agitation) in room temperature under argon
atmosphere, followed by ﬁltration and washing with DMF. Next, resin was ﬁltrated
and washed with DMF, Fmoc-protective groups were removed with 25%PIP/DMF
for 5, 5 and 25 min and the resin was washed with DMF. Next, 2 eq of Fmoc-Leu-
OH was activated with 2 eq HATU (Iris Biotech GmbH) and 2 eq of collidine and
coupled to the resin. Reaction was carried out for 3 h, followed by washing and
Fmoc-protective group removal. Peptide chain elongation was continued in the
same manner until the last amino acid. Next, last Fmoc-protective group was
removed, 1 eq of Cy5-NHS (Lumiprobe) was dissolved in DMF and 5 eq of DIPEA
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was added, followed by pouring of reaction mixture onto the resin. Reaction was
carried out in room temperature for 2 h. Next, resin was washed with DMF, DCM
and MeOH, dried over P2O5 for 3 h and peptides were cleaved from the resin with
TFA:DCM:TIPS (44.5:44.5:1, v:v:v). Crude product was precipitated in diethyl
ether, puriﬁed with HPLC (Waters, column: Sperisorb, 5 μm particle size, L x I.D >
25 cm × 4.6 mm) using a H2O:acetonitrile gradient and lyophilised. Compounds
were analysed with HPLC and HRMS.
NMR studies. 15N-labelled UBC9 proteins were prepared at 20 µM or 50 µM in a
buffer containing 100 mM sodium phosphate, pH 6.0, 5 mM dithiothreitol, 0.02%
NaN3, and 10% D2O42. All NMR spectra were collected at 298 K on a Bruker
Ascend 700 spectrometer. WT peptide (3.4 mM) and K689R peptide (2.4 mM)
were stepwise titrated into UBC9 and chemical shift perturbation were monitored
in series of the 1H-15N HSQC spectra. The dissociation constant Kd was estimated
using chemical shift changes as a function of the peptide:UBC9 molar ratios of the
indicated residue in the proton dimension.
In vitro sumoylation assay. In vitro sumoylation assays were conducted by
incubating the reaction mixture (30 μl) containing 0.78 μM E1, 8.4 μM peptide,
0.35 µM UBC9, 22.7 µM SUMO-1 or GST-fusion-SUMO-3, and 4 mM ATP in
assay buffer (5 mM MgCl2, 0.1% Tween-20, 50 mM NaCl, 20 mM HEPES pH 7.6)
for 15 min at 37 °C. Two different peptides (WT, K689R mutant) were tested in the
presence and absence of ATP. Reactions were quenched with 30 µl 360 mM DTT
loading buffer and components were separated using SDS-PAGE. Gels were
imaged using Typhoon™ 9410 Variable Mode Imager.
Denaturing sumoylation assay HEK293T. For sumoylation and ubiquitination
assays 2 × 106 HEK293T cells were plated in 10 cm dishes and transfected with a
total of 7.5 μg of DNA the following day. A modiﬁed version of “Detection of
Sumoylated Proteins by Immunoprecipitation Analysis”61 was used. Brieﬂy, 16 h
post-transfection cells were lysed in SDS lysis buffer (1% SDS, 0.15M Tris-HCl pH
6.8 and 30% Glycerol). Lysates were boiled for 5 min and diluted 10 × in PBS-T
(PBS and 1% Triton-X 100) supplemented with PR-619 (50 μM) and complete
protease inhibitors. Cell lysates were sonicated for 20 s then clariﬁed at 4 °C at
13,000 rpm for 10 min. A 20 μl of α-HA beads (SIGMA) or α-FLAG M2 beads
(SIGMA) was rotated with cleared protein lysates at 4 °C for 4 h. Furthermore, 4×
washes in PBS-T, supplemented with PR-619 (20 μM) and complete protease
inhibitors, were performed, and samples eluted by boiling in 60 μl 1× SDS loading
dye. Samples were separated by SDS-PAGE using Bolt 8% Bis-Tris plus 1.0 mm 12
well precast protein gels (Life Technologies) in MOPS buffer. Where necessary, the
modiﬁcation smears were quantiﬁed using Image Lab Software (Bio-Rad) and
normalised to total immunoprecipitated NLRP3 in biological triplicate. A two-
tailed Student’s t-test was performed on log2-transformed fold change compared to
WT NLRP3 using Prism 7, Graphpad.
BMDM sumoylation assay. NLRP3 sumoylation was assayed by immunopreci-
pitating NLRP3 from N1-8 BMDMs using α-FLAG M2 beads (SIGMA) as
described previously15. Furthermore, 10 mM N-ethylmaleimide was replaced with
20 μM PR-619, and immunoprecipitates were separated by SDS-PAGE using Bolt
8% Bis-Tris plus 1.0 mm 12 well precast protein gels (Life Technologies) in MOPS
buffer.
Caspase-1 cleavage assay. For caspase-1 cleavage assays 1 × 105 HEK293T-ASC-
caspase-1 cells were plated in 24-well plates and transfected with a total of 600 ng
of DNA the following day. Cells were lysed in 80 μl of DISC lysis buffer (20 mM
Tris-HCL pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10% Glycerol)
supplemented with 2% SDS. To shred genomic DNA cell lysates were passed
through 0.8 ml columns (Pierce). Lysates were quantiﬁed using BCA protein assay
kit (Pierce) and 6× SDS loading dye added. Samples were boiled for 5 min before
separating by SDS-PAGE using NuPAGE Novex 4–12% Bis-Tris 1.0 mm 20 well
precast midi protein gels (Life Technologies) in MES buffer. Caspase-1 p20 anti-
body (Bally-1, human, Adipogen) was used to detect total and cleaved caspase-1 in
cell lysate.
MAPL immunoprecipitation. HEK293T cells were transfected with the indicated
plasmids. Approximately 24 h after transfection, cells were lysed in 20 mM Tris pH
7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol and 2 mM EDTA containing
complete protease inhibitor cocktail (Roche). Immunoprecipitations were per-
formed using α-FLAG or α-HA agarose beads (Sigma) overnight. Samples were
eluted by addition of 0.2 M glycine, separated by SDS-PAGE and examined by
Western blot analysis.
ASC oligomerization. ASC oligomerization was performed as described in59 with
minor adaptions. BMDMs were seeded at 1 × 106 cells/ml in six-well plates 48-post
siRNA treatment. Following short LPS priming and nigericin stimulation the cells
were washed in ice-cold PBS and lysed in 500 μl of ice-cold buffer (20 mM HEPES-
KOH, pH 7.5, 150 mM KCL, 1% NP-40, HALT protease inhibitor) by shearing
times through a 21-gauge needle. Approximately, 50 μl of lysate was removed for
western blot analysis. The remaining lysates was centrifuged at 6000 rpm for
10 min at 4 °C. The pellets were washed in ice-cold PBS and resuspended in 500 μl
of PBS. Furthermore, 2 mM disuccinimydyl suberate (DSS) was added to the
resuspended pellets, which were incubated at room temperature for 30 min with
rotation. Samples were then centrifuged at 6000 rpm for 10 min at 4 °C. The
supernatant was removed, and the cross-linked pellets were resuspended in 30 μl of
Laemmli sample buffer. Samples were boiled for 5 min at 99 °C and analysed by
western blotting.
Confocal microscopy and PLA. For immunoﬂuorescence staining, 1.5 × 105 cells
were plated on 13 mm glass cover slips (VWR). Cells were either left untreated, or
treated with LPS (500 ng/ml) for 4 h followed or not by 10 µM nigericin for 30 min
or 5 mM ATP for 20 min, before being ﬁxed in 4% paraformaldehyde for 10 min.
Following 10 min permeabilization with PBS containing 0.5% Triton X-100, cells
were incubated for 1 h in 5% BSA in PBS. Respective primary antibodies were then
added as follows: mouse α-NLRP3 (AG-20B-0014, AdipoGen, 1:1000), rabbit α-
SUMO-2/3 (4971, Cell Signalling, 1:1000), rabbit α-ASC (AG-25B-0006, Adipo-
Gen, 1:200) and rabbit α-MAPL (ab84067, Abcam, 1:1000). Alexa Fluor 633-
conjugated Phalloidin (Invitrogen, 1:500) was used to stain actin ﬁlaments. Sec-
ondary ﬂuorescent conjugated antibodies were then added as follows: 1:1000
CF488A-donkey α-mouse and 1:1000 CF488-donkey α-rabbit. Nuclei were stained
with DAPI (Invitrogen). Cells were visualised by confocal microscopy (objective×
40, Zeiss LSM710). PLA was performed according to the manufacturer’s protocol
using the Duolink Detection Kit (Cambridge BioScience Ltd). Immunoﬂuorescence
staining of NLRP3, SUMO-2/3, ASC, and MAPL (same antibodies as above, all
1:50) for the Duolink was carried out following the above-described protocol for
immunoﬂuorescence detection up until the primary antibody incubation step.
Probe incubation, ligation and ampliﬁcation reaction were carried out according to
the manufacturer instructions. Cy3 signal ampliﬁcation was used for the assay.
Cells were examined with a confocal microscope (objective× 40, Zeiss LSM 710).
The number of ﬂuorescent spots in 50 cells were quantiﬁed using ImageJ and data
analysed using two-way ANOVA multiple comparison test or two-tailed Student’s
t-test using Prism 7, Graphpad.
IL-1β ELISA. The amount of IL-1β present the in the culture supernatant following
inﬂammasome activation using long LPS priming was analysed using the Mouse
IL-1β ELISA Ready-SET-Go! Kit (eBioscience) according to the manufacturer’s
instructions. The fold change compared to control (non-targeting siRNA) was
calculated for three individual experiments and two-tailed Student’s t-test was
performed on the log2-transformed data using Prism 7, Graphpad.
Fig. 6 Depletion of SENP6 and SENP7 reduces NLRP3 inﬂammasome activity. a The indicated BMDMs were transfected with non-targeting, Senp6 or
Senp7-speciﬁc siRNAs and primed with LPS (10min). Cells were subsequently stimulated with ATP (1 h) or cytoplasmic DNA (3 h). Representative
immunoblot analysis of cleaved caspase-1 in cell supernatant (S/N) and ASC, caspase-1 and NLRP3 in the cellular lysate. b The indicated BMDMs were
transfected with the respective siRNAs. Cells were primed with LPS (10min) and stimulated with nigericin (90min). Representative immunoblot analysis
of cleaved caspase-1 in cell supernatant (S/N) and ASC, caspase-1 and NLRP3 in the cellular lysate. c ASC oligomerisation assay. BMDMs were treated
with the indicated agents. Cells were lysed and insoluble pellets cross-linked with Sulfo-DSS. Representative immunoblot analysis of ASC present in the
insoluble pellet (pellets) and soluble fraction (lysates). Graph depicts the quantiﬁcation of ASC oligomerisation (region indicated by dotted lines). d The
indicated BMDMs were treated with nigericin. Immunoblot analysis of cleaved caspase-1 in the cell supernatant (S/N) and ASC, caspase-1 and NLRP3 in
the cellular lysate. e The indicated BMDMs were treated with LPS for 4 h and stimulated with nigericin (90min). IL-1β levels in the cell supernatant were
measured by ELISA. Individual data points of three independent experiments are presented as fold change compared to Ctrl N1-8 BMDMs (non-targeting
siRNA). Grey bar represents mean ± SEM. *P < 0.05; two-tailed Student’s t-test on log2-transformed data comparing nigericin treated BMDMs transfected
with Senp7-speciﬁc siRNA to Ctrl BMDMs
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Bioinformatic analysis. Putative SUMOylation sites in NLRP3 were identiﬁed
using GPS-SUMO26, SUMOplot analysis (Abgent) software, JASSA25 and Ron
Hay’s SUMO consensus motif search tool (www.lifesci.dundee.ac.uk/groups/
ron_hay/pages/SumomotifQuery.html). GPS-SUMO was also used to predict
SUMO-interaction motifs (SIMs) in NLRP3.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its supplementary information ﬁles, or are
available upon reasonable requests to the authors.
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